MacroGenics, Inc. (MGNX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Eric Blasius Risser
|
CEO, President & Director | 977.47k | -- | 1973 |
|
Mr. James Karrels
|
Senior VP & CFO | 845.55k | -- | 1967 |
|
Dr. Ezio Bonvini M.D.
|
Senior VP of Research & Chief Scientific Officer | 881.4k | -- | 1954 |
|
Dr. Araba Lamouse-Smith Ph.D.
|
Vice President of Technical Operations | -- | -- | -- |
|
Mr. Jeffrey Stuart Peters J.D.
|
Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer | -- | -- | 1971 |
|
Mr. Steve Harig
|
Senior Vice President of Human Resources | -- | -- | -- |
|
Mr. Harish Krishnaswamy
|
Senior Vice President of Business Development & Portfolio Planning | -- | -- | -- |
|
Dr. Frank George Perabo FEBU, M.D., Ph.D.
|
Vice President & Interim Head of Clinical Development | -- | -- | 1964 |
|
Ms. Beth Smith
|
VP, Controller & Treasurer | -- | -- | 1968 |
MacroGenics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 293
Description
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Corporate Governance
Upcoming Events
November 12, 2026 at 8:00 PM UTC
MacroGenics, Inc. Earnings Date
